References
- CazoriaPMackleMZhaoJHaXSzegediASafety and tolerability of switching to asenapine from other antipsychotic agents: pooled results from two randomized multicenter trials in stable patients with persistent negative symptoms in schizophreniaNeuropsychiatr Dis Treat2012824725722745558
- CacciaSPasinaLNobiliACritical appraisal of lurasidone in the management of schizophreniaNeuropsychiatr Dis Treat2012815516822570547
- Ascher-SvanumHBrnabicAJMLawsonAHComparison of patients undergoing switching versus augmentation of antipsychotic medications during treatment for schizophreniaNeuropsychiatr Dis Treat2012811311822536066
- YeWAscher-SvanumHTanjiYFlynnJATakahashiMConleyRRAntipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a healthcare database analysisNeuropsychiatr Dis Treat1012825926622745559
- MossahebNKaufmannRMRole of aripiprazole in treatment-resistant schizophreniaNeuropsychiatr Dis Treat2012823524422701324
- GotoNYoshimuraRKakedaSSix-month treatment with atypical antipsychotic drugs decreased frontal-lobe levels of glutamate plus glutamine in early-stage first-episode schizophreniaNeuropsychiatr Dis Treat2012811912222536067
- MarinoJEnglishCCaballeroJHarringtonCThe role of paliperidone extended release for the treatment of bipolar disorderNeuropsychiatr Dis Treat2012818118922570550
- HuysDHardenackeKPoppePBartschCBaskinBKuhnJUpdate on the role of antipsychotics in the treatment of Tourette syndromeNeuropsychiatr Dis Treat201289510422442630
- YilmazASimsekFGonulASReduced reward-related probability learning in schizophrenic patientsNeuropsychiatr Dis Treat20128273422275843